Studies on ovarian cancer have suggested that crucial enzymes that mediate metabolic reprogramming, such as FASN and CPT1A, are overexpressed in tumor tissues, which is associated with poor prognosis and survival rates [23,34]. This evidence concerns the gene CPT1A and neoplasm.